An internationally recognized expert in radiation therapy for gastrointestinal (GI) cancers, Michael Chuong, M.D., FACRO, is vice chair and medical director of radiation oncology and leads the GI radiation service at the Miami Cancer Institute, Baptist Health South Florida.
Dr. Chuong earned his medical degree from the University of South Florida College of Medicine and completed his residency training in radiation oncology at the H. Lee Moffitt Cancer Center, where he served as the chief resident.
He also serves as the vice chair of education and clinical research and is professor of radiation oncology at the Florida International University Herbert Wertheim College of Medicine.
Dr. Chuong is frequently invited to speak around the globe about his clinical expertise and research that is impacting the standard of care, especially related to proton therapy and MRI-guided radiation therapy. Dr. Chuong has co-authored over 125 peer-reviewed manuscripts in prestigious journals such as JAMA Oncology and the International Journal of Radiation Oncology Biology Physics, for which he is the GI section editor.
He is a principal investigator for multiple national and international clinical trials that are exploring advanced radiation therapy strategies and unique combinations of radiation therapy with novel therapeutic agents for GI cancers. An active leader in the medical community, Dr. Chuong is the Protocol Monitoring and Review Committee chair at Baptist Health Miami Cancer Institute, Disease Site chair of the Proton Collaborative Group and the Particle Therapy Co-operative Group Gastrointestinal Subcommittee co-chair. He participates as an active member of the NRG Oncology Non-Colorectal GI subcommittee, NRG Oncology Pancreas Working Group, and NRG Oncology International Liaison committee.

Ian began his career as a Medical Physicist in 1989, working at the Hammersmith hospital, London.
Since 1998 he has worked almost exclusively in the field of SRS, being responsible for over 8,000 patient treatments and has helped start up over 100 centres worldwide. He is considered a world authority on treatment plan metrics, having formulated the Paddick Conformity Index and the Gradient Index.
In 2003, Ian became a freelance physicist and set up Medical Physics Limited; a group of physicists providing expert radiosurgery physics services to SRS centres in the UK, Europe and the USA, as well as industry.
Ian is currently on the faculty of five SRS centres; Queen Square, London, GenesisCare at Cromwell, London, London Gamma Knife Centre, Thornbury Radiosurgery Centre, Sheffield and St. Elisabeth Hospital, Tilburg, Netherlands.
He was the first physicist to serve as President of the International Stereotactic Radiosurgery Society (ISRS) and received Fabrikant Award for his contribution to SRS.
He currently serves as President to the British Radiosurgery Society and Chair of the ISRS Certification Committee.

Dr. Jillian Tsai is a Staff Radiation Oncologist at Princess Margaret Cancer Centre and Associate Professor in the Department of Radiation Oncology at the University of Toronto. She leads the Allan and Ruth Kerbel Palliative Radiation and Oligometastases Program (PROP) and is a member of the Head and Neck Site Group. She also serves as the Medical Director of Princess Margaret Cancer Registry. Prior to joining Princess Margaret Cancer Centre in September 2022, she practiced radiation oncology at Memorial Sloan Kettering Cancer Center in New York City from 2014 to 2022. Dr. Tsai completed residency training at MD Anderson Cancer Center after receiving her MD degree from Vanderbilt University. In addition, she holds a PhD degree in Cancer Epidemiology from Stanford University. Her research interests include biomarker-driven clinical trials and population-based studies.
Dr. Tsai is a recipient of several prestigious grants and awards, including the Eleanor Montague Distinguished Resident Award in Radiation Oncology by American Association for Women Radiologists, Steven A. Leibel Memorial Award by American Society for Radiation Oncology, and Till and McCulloch Paper of the Year at Princess Margaret Cancer Centre.

Dr. Amy Chang is currently Honorary Consultant in Clinical Oncology at Hong Kong Sanatorium & Hospital, co-director of HKSH proton therapy centre, Honorary Clinical Associate Professor (CUHK) and Honorary Clinical Assistant Professor of the Department of Clinical Oncology, The University of Hong Kong. She obtained Bachelor of Science in Biological Chemistry at University of Chicago, and graduated from The University of Hong Kong in 2002. After internship she was trained in Department of Clinical Oncology of Pamela Youde Nethersole Eastern Hospital. She is a fellow of the Royal College of Radiologists and Hong Kong College of Radiologists (2012). She is the steering committee member for Asia-Oceania Particle Therapy Co-operative group (PTCOG-AO).  She received overseas training in Medical College of Wisconsin, USA, Cambridge University UK, Medical University of Vienna and to Mayo Clinic Arizona. Her subspecialty interests include breast and gynecological cancers, MRI-based radiotherapy and brachytherapy, gastrointestinal and pediatrics cancers, and proton therapy applications.

Dr. Chiang graduated from the Chinese University of Hong Kong. He has completed post-fellowship training in Princess Margaret Hospital and Johns Hopkins Hospital before joining University of Hong Kong as Clinical Assistant Professor (Clinical Oncology).
His research interest focuses on the utilization of stereotactic body radiotherapy (SBRT) combination in treating hepatocellular carcinoma (HCC). He has pioneered a novel tri-modality treatment called START-FIT, which converted around 50% of incurable HCC into a curable disease with long-term survival. This innovative discovery has been published in Lancet Gastroenterology and Hepatology, JAMA Oncology, and Liver Cancer, and adopted as one of the recommended treatment strategies in the National Treatment Guideline of HCC. His works have been recognized by numerous accolades, including Faculty Best Research Award 2023, Gold Medal Prize for Best Original Research by Young Fellows of Hong Kong Academy of Medicine 2023, Best Presentation Award of 13th Asia-Pacific Primary Liver Cancer Expert Meeting 2023, and Special Grand Prize of the 49th International Exhibition of Inventions of Geneva. He has collaborated with Liver Transplantation Team to successfully cure a terminal liver cancer patient by using the START-FIT followed by liver transplantation, an achievement that was named among the ‘Top Ten Hong Kong Innovation and Technology News in 2023’.
Dr. Chiang contributed to over 65 articles in international peer-review journals including Lancet Gastroenterology and Hepatology, JAMA Oncology, Gut, and Liver Cancer. He also contributes to the development of advanced radiation research in Hong Kong. He is the current president and co-founder of the Hong Kong SBRT Study Group and School Principal of Gleneagles Hospital Radiotherapy School.